Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial
K. Wolff
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorC. Fleming
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorJ. Hanifin
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorK. Papp
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorS. Reitamo
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorM. Rustin
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorN. Shear
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorW. Silny
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorN. Korman
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorI. Marks
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorR. Cherill
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorS. Emady-Azar
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorC. Paul
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorthe Multicentre Investigator Group
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorK. Wolff
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorC. Fleming
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorJ. Hanifin
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorK. Papp
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorS. Reitamo
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorM. Rustin
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorN. Shear
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorW. Silny
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorN. Korman
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorI. Marks
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorR. Cherill
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorS. Emady-Azar
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorC. Paul
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorthe Multicentre Investigator Group
Department of Dermatology, Medical University of Vienna, Austria *Ninewells Hospital and Medical School, Dundee, U.K.†Oregon Health and Science University, Portland, OR, U.S.A.‡Probity Medical Research, Waterloo, Ontario, Canada§Hospital for Skin and Allergic Disease, Helsinki, Finland¶Royal Free Hospital, London, U.K.**University of Toronto and Ventana Clinical Research, Toronto, Canada††Poznań University of Medical Sciences, Poznań, Poland‡‡Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, U.S.A.§§Clinical Research, Novartis Pharmaceuticals Inc., East Hanover, NJ, U.S.A.¶¶Clinical Research Dermatology, WSJ 210.9.13, Novartis Pharma AG, CH-4002, Basel, Switzerland
Search for more papers by this authorConflicts of interest: K.W. has received research grants from Novartis but holds no personal or financial interest in the company; S.R. has participated in clinical studies for Novartis Pharma and Fujisawa GmbH; R.C., I.M., S.E-A. and C.P. are employees of Novartis.
Summary
Background Adult atopic dermatitis (AD) can seriously affect quality of life of patients and their families, and patients' disease is frequently not satisfactorily controlled with topical therapy. There is a need for alternatives to topical treatment in patients with moderate to severe AD.
Objectives To investigate the efficacy and safety of oral pimecrolimus, and to determine the response to three different doses in the treatment of AD.
Methods In a double-blind, placebo-controlled, parallel-group, dose-finding study, patients with moderate to severe AD were randomized to receive either placebo, or oral pimecrolimus 10, 20 or 30 mg twice daily. The study consisted of a pretreatment phase, a 12-week double-blind treatment phase, and a 12-week post-treatment phase.
Results In total, 103 patients were randomized. A clear, dose-dependent therapeutic effect of pimecrolimus treatment was observed, with a statistically significant onset of efficacy at week 2 and the greatest reduction from baseline of the Eczema Area and Severity Index of 66·6% at week 7 in the 30 mg twice daily dose group. Oral pimecrolimus was well tolerated and there were no signs of nephrotoxicity or the induction of hypertension.
Conclusions These data demonstrate the clinically relevant efficacy and short-term safety of oral pimecrolimus in adults with moderate to severe AD. Longer-term studies in larger cohorts are now required.
References
- 1 Hepburn D, Yohn JJ, Weston WL. Topical steroid treatment in infants, children, and adolescents. Adv Dermatol 1994; 9: 225–54.
- 2 Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila) 2000; 39: 1–14.
- 3 Bernard LA, Eichenfield LF. Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr 2002; 14: 414–18.
- 4 Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin Exp Dermatol 2000; 25: 559–66.DOI: 10.1046/j.1365-2230.2000.00697.x
- 5 Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol 1986; 14: 161–77.
- 6 Akhavan A, Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clin Dermatol 2003; 21: 225–40.DOI: 10.1016/S0738-081X(02)00362-0
- 7 Berth-Jones J, Takwale A, Tan E et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002; 147: 324–30.
- 8 Zaki I, Emerson R, Allen BR. Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol 1996; 135 (Suppl. 48): 21–4.
- 9 Zachariae H. Renal toxicity of long-term cyclosporin. Scand J Rheumatol 1999; 28: 65–8.DOI: 10.1080/030097499442504
- 10 Grassberger M, Baumruker T, Enz A et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264–73.DOI: 10.1046/j.1365-2133.1999.02974.x
- 11 Hultsch T, Muller KD, Meingassner JG et al. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998; 290: 501–7.DOI: 10.1007/s004030050343
- 12 Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004; 5: 643–55.DOI: 10.1517/14656566.5.3.643
- 13 Rappersberger K, Komar M, Ebelin ME et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002; 119: 876–87.DOI: 10.1046/j.1523-1747.2002.00694.x
- 14 Griffiths C, Dubertret L, Gottlieb AB. Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose–response effect. J Invest Dermatol 2003; 121: Abstract 0391.
- 15 Barbier N, Paul C, Luger T et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004; 150: 96–102.
- 16 Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495–504.DOI: 10.1067/mjd.2002.122187
- 17 Sowden JM, Berth-Jones J, Ross JS et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338: 137–40.DOI: 10.1016/0140-6736(91)90134-B
- 18 Berth-Jones J, Graham-Brown RAC, Marks R et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997; 136: 76–81.
- 19 Meagher LJ, Wines NY, Cooper AJ. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 2002; 43: 247–54.DOI: 10.1046/j.1440-0960.2002.00610.x
- 20 Granlund H, Erkko P, Sinisalo M et al. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995; 132: 106–12.
- 21 Krutmann J, Diepgen TL, Luger TA et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998; 38: 589–93.
- 22 Paul C, Lahfa M, Bachelez H et al. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002; 147: 518–22.DOI: 10.1046/j.1365-2133.2002.04833.x
- 23 Sasaki K, Kojima M, Nakaizumi H et al. Early lens changes seen in patients with atopic dermatitis applying image analysis processing of Scheimpflug and specular microscopic images. Ophthalmologica 1998; 212: 88–94.DOI: 10.1159/000027285
- 24 Matsuo T, Saito H, Matsuo N. Cataract and aqueous flare levels in patients with atopic dermatitis. Am J Ophthalmol 1997; 124: 36–9.
